GHLF supports MT HB 233
HB 233 takes positive steps toward updating Montana law to cover biologics and biosimilars in a way that protects patients. Unlike traditional chemical drugs, biologics are unique, complex structures made from living cells that are not easily replicated. A small change or difference in the biosimilar or biologic manufacturing process has the potential to adversely impact the patient. At its core, HB 233 boils down to two words: Trust and transparency. The patient-physician relationship and positive health outcomes do not exist without them.
Click here to read full Testimony